All In Biotech

Drug Trial Radar · NCT06186037

Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention

Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention : A Prospective, Multicenter, Randomized, Open-label Trial

Last checked: Nov 20, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 6,356 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

6,356

Planned (sponsor's estimate)

Start

Feb 1, 2024

Primary completion

Feb 28, 2029

Study completion Feb 28, 2029

Sponsor

Lead sponsor
Saint Vincent's Hospital, KoreaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

\[Purpose of the Clinical Study\]:The purpose of this study is to conduct a clinical comparison of low-dose rosuvastatin plus ezetimibe combination therapy and high-dose rosuvastatin monotherapy in patients with minimal to intermediate coronary artery disease without percutaneous coronary intervention to confirm non-inferiority in the reduction of key cardiovascular events. \[Hypothesis\]:In patients who have not undergone percutaneous coronary intervention for minimal to moderate coronary artery disease, low-dose rosuvastatin and ezetimibe combination therapy are non-inferior in terms of reducing major cardiovascular events compared to high-dose rosuvastatin monotherapy.

Conditions

  • Coronary Artery Disease
  • Dyslipidemias
  • Primary Prevention

Interventions

  • Combination drug group of Ezetimibe 10 mg/Rosuvastatin 5 mgDrug

    Oral administration once a day, taking it for 3 years

  • Mono drug group of Rosuvastatin 20 mgDrug

    Oral administration once a day, taking it for 3 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The occurrence rates of the compound variablesTime frame: Visit 5 (36month)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St. Vincent's Hospital

    Suwon, Gyeonggi-do, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.